Vaughan David Investments LLC IL Purchases 7,472 Shares of Zoetis Inc. $ZTS

Vaughan David Investments LLC IL increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.6% during the fourth quarter, HoldingsChannel.com reports. The firm owned 217,318 shares of the company’s stock after buying an additional 7,472 shares during the period. Vaughan David Investments LLC IL’s holdings in Zoetis were worth $27,343,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after purchasing an additional 5,474,210 shares during the period. Geode Capital Management LLC increased its position in shares of Zoetis by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock valued at $1,420,294,000 after purchasing an additional 189,235 shares during the period. Norges Bank bought a new stake in Zoetis in the fourth quarter valued at $734,425,000. Deutsche Bank AG grew its position in Zoetis by 19.1% in the fourth quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock valued at $699,331,000 after acquiring an additional 891,921 shares during the period. Finally, Nordea Investment Management AB grew its position in Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after acquiring an additional 2,179,578 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Michael B. Mccallister purchased 3,000 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the purchase, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. The trade was a 13.94% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Frank A. Damelio purchased 6,650 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were purchased at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the purchase, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 11,650 shares of company stock valued at $886,384 over the last 90 days. 0.22% of the stock is owned by company insiders.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms, including Rosen, Bronstein Gewirtz & Grossman, the Schall Law Firm, DJS Law Group, and others, urged investors to join or lead a class action against Zoetis, keeping litigation risk in focus and potentially weighing on sentiment. Article Title
• Negative Sentiment: The lawsuits allege Zoetis misled investors about weakening veterinarian adoption and prescription trends, which could raise concerns about the company’s underlying growth outlook and create overhang on the stock. Article Title
• Neutral Sentiment: Rosen Law Firm and others reminded shareholders that July 27, 2026 is the lead-plaintiff deadline, but these notices are procedural and do not change Zoetis’ fundamentals by themselves. Article Title
• Neutral Sentiment: Bank of America Securities reportedly maintained a “Hold” rating on Zoetis, which suggests Wall Street remains cautious but not overtly bearish. Article Title

Zoetis Price Performance

Shares of ZTS stock opened at $81.51 on Friday. The stock’s fifty day moving average is $97.70 and its 200-day moving average is $114.47. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The stock has a market capitalization of $34.17 billion, a PE ratio of 13.52, a PEG ratio of 1.27 and a beta of 0.75. Zoetis Inc. has a 52 week low of $72.38 and a 52 week high of $168.83.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter in the previous year, the company posted $1.48 EPS. Zoetis’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts expect that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is 35.16%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Morgan Stanley reiterated an “overweight” rating and issued a $115.00 price target on shares of Zoetis in a research report on Friday, May 15th. Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. UBS Group lowered their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research report on Friday, May 8th. Stifel Nicolaus lowered their price target on Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a research report on Friday, May 22nd. Finally, JPMorgan Chase & Co. lowered their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Six research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Zoetis currently has an average rating of “Hold” and a consensus price target of $133.92.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.